Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMPRSS11D | O60235 | 12/20 | 0.55 |
| ▸ | F2 | P00734 | 7/20 | 0.53 |
| ▸ | F10 | P00742 | 4/20 | 0.53 |
| ▸ | PLG | P00747 | 3/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | XIAP | P98170 | 2/20 | 0.45 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.45 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.45 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7156972 | 0.99 | TMPRSS11D (0.55) | TMPRSS11DF2F10PLGCYP3A4 | |
| SCHEMBL7463433 | 0.96 | TMPRSS11D (0.51) | TMPRSS11DF2F10PLGXIAP | |
| Hydrochloric Acid SCHEMBL7156462 | 0.95 | TMPRSS11D (0.50) | TMPRSS11DF2F10PLGXIAP | |
| SCHEMBL7105052 | 0.89 | TMPRSS11D (0.58) | TMPRSS11DF2F10PLG | |
| SCHEMBL7106028 | 0.89 | TMPRSS11D (0.68) | TMPRSS11DF2F10PLG | |
| Hydrochloric Acid SCHEMBL7140902 | 0.88 | TMPRSS11D (0.67) | TMPRSS11DF2F10PLG | |
| SCHEMBL7363339 | 0.86 | TMPRSS11D (0.49) | TMPRSS11DF2F10PLGCYP3A4 | |
| Hydrochloric Acid SCHEMBL7154381 | 0.86 | F2 (0.50) | TMPRSS11DF2F10PLGPRSS1 | |
| Hydrochloric Acid SCHEMBL7154388 | 0.86 | F2 (0.50) | TMPRSS11DF2F10PLGPRSS1 | |
| Hydrochloric Acid SCHEMBL7156980 | 0.85 | TMPRSS11D (0.49) | TMPRSS11DF2F10PLGCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0816376-B1 | Trombin inhibitors as anticoagulant agents | LILLY CO ELI (US) | 2002-11-06 | — | — | EP | claimed |
| US-20010018423-A1 | Anticoagulant agents | KLIMKOWSKI VALENTINE J (US) | 2001-08-30 | — | — | US | claimed |
| US-6200967-B1 | USED AS THROMBIN INHIBITORS, COAGULATION INHIBITORS AND AGENTS FOR THE TREATMENT OF THROMBOEMBOLIC DISORDERS | ELI LILLY AND COMPANY | 2001-03-13 | — | — | US | claimed |
| EP-0816376-A1 | Trombin inhibitors as anticoagulant agents | ELI LILLY AND COMPANY (US) | 1998-01-07 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010018423-A1 | Anticoagulant agents | SERPINC1, F12, F11 | TMPRSS11D 1128/4885F2 4/4885F10 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.